Show simple item record

dc.contributor.authorAdes, AE
dc.contributor.authorBiswas, M
dc.contributor.authorWelton, NJ
dc.contributor.authorHamilton, W
dc.date.accessioned2016-07-04T15:09:22Z
dc.date.issued2014-08-29
dc.description.abstractBackground: Before their diagnosis, patients with cancer present in primary care more frequently than do matched controls. This has raised hopes that earlier investigation in primary care could lead to earlier stage at diagnosis. Methods: We re-analysed primary care symptom data collected from 247 lung cancer cases and 1235 matched controls in Devon, UK. We identified the most sensitive and specific definition of symptoms, and estimated its incidence in cases and controls prior to diagnosis. We estimated the symptom lead time (SLT) distribution (the time between symptoms attributable to cancer and diagnosis), taking account of the investigations already carried out in primary care. The impact of route of diagnosis on stage at diagnosis was also examined. Results: Symptom incidence in cases was higher than in controls 2 years before diagnosis, accelerating markedly in the last 6 months. The median SLT was under 3 months, with mean 5.3 months [95% credible interval (CrI) 4.5–6.1] and did not differ by stage at diagnosis. An earlier stage at diagnosis was observed in patients identified through chest X-ray originated in primary care. Conclusions: Most symptoms preceded clinical diagnosis by only a few months. Symptom-based investigation would lengthen lead times and result in earlier stage at diagnosis in a small proportion of cases, but would be far less effective than standard screening targeted at smokers.en_GB
dc.description.sponsorshipThis work was supported by the National Institute for Health Research (NIHR) Programme Grants for Applied Research Programme, RP-PG-0608–10045. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The funders of this study had no role in: study design; data collection, analysis, and interpretation; or the writing of this research paper. The corresponding author had full access to all data and final responsibility for the decision to submit for publication.en_GB
dc.identifier.citationVol. 43, pp. 1865 - 1873en_GB
dc.identifier.doi10.1093/ije/dyu174
dc.identifier.urihttp://hdl.handle.net/10871/22382
dc.language.isoenen_GB
dc.publisherOxford University Press (OUP)en_GB
dc.subjectLung canceren_GB
dc.subjectlead timeen_GB
dc.subjectsymptom lead timeen_GB
dc.subjectstage at diagnosisen_GB
dc.titleSymptom lead time distribution in lung cancer: natural history and prospects for early diagnosisen_GB
dc.typeArticleen_GB
dc.date.available2016-07-04T15:09:22Z
dc.identifier.issn0300-5771
dc.descriptionThis is the author accepted manuscript. The final version is available from Oxford University Press via the DOI in this record.en_GB
dc.identifier.journalInternational Journal of Epidemiologyen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record